低潮气量通气联合体外二氧化碳清除对急性低氧性呼吸衰竭90天死亡率的影响:REST随机临床试验
REST多中心随机开放标签实用性试验纳入412例急性低氧性呼吸衰竭机械通气成人患者,比较体外二氧化碳清除辅助低潮气量通气与常规低潮气量通气。90天死亡率两组无显著差异(41.5% vs 39.5%;RR 1.05,95%CI 0.83-1.33;
要点
- 体外二氧化碳清除辅助低潮气量通气未降低90天死亡率。
- 干预组28天无呼吸机天数显著减少(7.1 vs 9.2天)。
- 干预组严重不良事件更多,包括颅内出血9例vs 0例。
核心结论
- 在急性低氧性呼吸衰竭患者中,体外二氧化碳清除辅助低潮气量通气与常规低潮气量通气相比未显著降低90天死亡率。
- 因试验提前终止,研究可能把握度不足,无法检测临床重要差异。
研究设计与样本
- 多中心、随机、分配隐藏、开放标签、实用性临床试验,在英国51个重症监护病房进行。
- 计划样本量1120例,实际纳入412例成人急性低氧性呼吸衰竭机械通气患者,2016年5月至2019年12月入组,随访至2020年3月11日。
- 干预组202例接受体外二氧化碳清除辅助低潮气量通气至少48小时,对照组210例接受常规低潮气量通气。
主要发现
- 严重不良事件:干预组62例(31%),对照组18例(9%);颅内出血干预组9例(4.5%)vs对照组0例(0%);其他部位出血干预组6例(3.0%)vs对照组1例(0.5%)。
- 共21例患者发生22起与研究装置相关的严重不良事件。
临床怎么用
- 对于急性低氧性呼吸衰竭机械通气患者,不推荐常规使用体外二氧化碳清除辅助更低潮气量通气以改善生存。
- 使用体外二氧化碳清除需警惕出血(尤其颅内出血)等严重不良事件。
局限性
- 试验因无效性和可行性提前终止,实际样本量412例远低于计划1120例,可能把握度不足。
- 开放标签设计可能影响次要结局和不良事件报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: In patients who require mechanical ventilation for acute hypoxemic respiratory failure, further reduction in tidal volumes, compared with conventional low tidal volume ventilation, may improve outcomes. OBJECTIVE: To determine whether lower tidal volume mechanical ventilation using extracorporeal carbon dioxide removal improves outcomes in patients with acute hypoxemic respiratory failure. DESIGN, SETTING, AND PARTICIPANTS: This multicenter, randomized, allocation-concealed, open-label, pragmatic clinical trial enrolled 412 adult patients receiving mechanical ventilation for acute hypoxemic respiratory failure, of a planned sample size of 1120, between May 2016 and December 2019 from 51 intensive care units in the UK. Follow-up ended on March 11, 2020. INTERVENTIONS: Participants were randomized to receive lower tidal volume ventilation facilitated by extracorporeal carbon dioxide removal for at least 48 hours (n = 202) or standard care with conventional low tidal volume ventilation (n = 210). MAIN OUTCOMES AND MEASURES: The primary outcome was all-cause mortality 90 days after randomization. Prespecified secondary outcomes included ventilator-free days at day 28 and adverse event rates. RESULTS: Among 412 patients who were randomized (mean age, 59 years; 143 [35%] women), 405 (98%) completed the trial. The trial was stopped early because of futility and feasibility following recommendations from the data monitoring and ethics committee. The 90-day mortality rate was 41.5% in the lower tidal volume ventilation with extracorporeal carbon dioxide removal group vs 39.5% in the standard care group (risk ratio, 1.05 [95% CI, 0.83-1.33]; difference, 2.0% [95% CI, -7.6% to 11.5%]; P = .68). There were significantly fewer mean ventilator-free days in the extracorporeal carbon dioxide removal group compared with the standard care group (7.1 [95% CI, 5.9-8.3] vs 9.2 [95% CI, 7.9-10.4] days; mean difference, -2.1 [95% CI, -3.8 to -0.3]; P = .02). Serious adverse events were reported for 62 patients (31%) in the extracorporeal carbon dioxide removal group and 18 (9%) in the standard care group, including intracranial hemorrhage in 9 patients (4.5%) vs 0 (0%) and bleeding at other sites in 6 (3.0%) vs 1 (0.5%) in the extracorporeal carbon dioxide removal group vs the control group. Overall, 21 patients experienced 22 serious adverse events related to the study device. CONCLUSIONS AND RELEVANCE: Among patients with acute hypoxemic respiratory failure, the use of extracorporeal carbon dioxide removal to facilitate lower tidal volume mechanical ventilation, compared with conventional low tidal volume mechanical ventilation, did not significantly reduce 90-day mortality. However, due to early termination, the study may have been underpowered to detect a clinically important difference. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02654327.
引用
- McNamee JJ, Gillies MA, Barrett NA, et al. Effect of Lower Tidal Volume Ventilation Facilitated by Extracorporeal Carbon Dioxide Removal vs Standard Care Ventilation on 90-Day Mortality in Patients With Acute Hypoxemic Respiratory Failure: The REST Randomized Clinical Trial. JAMA. 2021. PMID: 34463700. doi:10.1001/jama.2021.13374
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。